Original Article |
| ![](/img/icon_oaccess.png) |
The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myelomaAyşe Uysal, Mehmet Ali Erkurt, İrfan Kuku, Emin Kaya, İlhami Berber, Ahmet Sarıcı, Soykan Biçim, Ahmet Kaya, Emine Hidayet, Betül Dağoğlu Hark, Süleyman Arslan. Abstract | | | | Objective: In this single-center, retrospective study, we aimed to evaluate the effect of CD34+ stem cell dose on hematologic recovery and long-term outcomes such as progression-free survival and overall survival after autologous stem cell transplantation (ASCT).
Materials and Methods: In this study, 282 patients with MM, who underwent ASCT between January 2014 and October 2021 were evaluated. The patients were divided into 2 groups according to the infused cell dose. Patients who received ≤5x106/kg CD34+ cells were defined as group A. Patients who received >5x106/kg CD34+ cells were group B. The outcome of ASCT including the time of neutrophil/platelet engraftment, febrile neutropenia status, transplant-related mortality (TRM) at 100 days, duration of hospitalization and survival status were examined in both groups.
Results: There were 118 (41.8%) patients in group A and 164 patients (58.2%) in group B. The median neutrophil engraftment was 12 (7-26) days in A group, 11 (6-28) days in B group. The median platelet engraftment was 12 (6-40) and 11 (6-29) days in group B. There were statically significant different in both group for neutrophil and platelet engraftment time (p=.001 and .002, respectively). The median hospitalization time was 16 (10-53) days and 15 (6-83) days in group A and B, respectively. The hospitalization time was statistically significantly different in two groups (p
Key words: autologous stem cell transplantation; CD34+ stem cell; neutrophil engraftment; platelet engraftment; survival
|
|
|
|